Skip to main content
. Author manuscript; available in PMC: 2020 Jun 25.
Published in final edited form as: Blood Rev. 2010 Feb 11;24(2):69–82. doi: 10.1016/j.blre.2010.01.001

Table 7.

Response rates of single agent mTOR inhibitors in NHL.

Study Status Agent Doses Patients Results (%)
ORR CR/CRu
Witzig et al. [123] Phase II Temsirolimus 250 mg IV weekly Relapsed/refractory MCL (n = 35) 38 3
Ansell et al. [124] Phase II Temsirolimus 25 mg IV weekly Relapsed/refractory MCL (n = 29) 41 4
Hess et al. [125] Phase III Temsirolimus 175 mg IV weekly × 3 followed by 75 mg Relapsed/refractory MCL (n = 54) 22 2
Smith et al. [126] Phase II Temsirolimus 25 mg IV weekly Relapsed/refractory non-MCL NHL (n = 82) 35 9
Reeder et al. [127] Phase II Everolimus 10 mg/day orally Relapsed/refractory NHL (n = 37) 32 3
Witzig et al. [128] Phase II Everolimus 10 mg/day orally Relapsed/refractory aggressive (n = 77) or indolent NHL or HL (n = 17) 33 3
Rizzieri et al. [129] Phase II Deforolimus 12.5 mg/day IV × 5 days every 2 weeks Relapsed/refractory hematological malignancies (n = 52) 10 0

CR – complete response; CRu – complete response unconfirmed; DLBCL – diffuse large B-cell lymphoma; HL – Hodgkin lymphoma; mTOR – mammalian target of rapamycin; MCL – mantle cell lymphoma; NHL – non-Hodgkin lymphoma; ORR – overall response rate.